Selective AT2 Receptor Agonists for Idiopathic Pulmonary Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), are limited in effectiveness and safety, with existing drugs causing significant side effects and offering only modest slowing of disease progression, highlighting the need for more potent and stable selective angiotensin II type 2 (AT2) receptor agonists that minimize CYP enzyme inhibition.
Innovation Solution
Development of chemically modified compounds that act as selective AT2 receptor agonists with improved metabolic stability and reduced CYP enzyme inhibition, specifically designed to target ILDs such as IPF, which are more potent and have enhanced stability compared to existing compounds like C21.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing AT2 receptor agonists are used to treat interstitial lung diseases, then some therapeutic effect is achieved, but they cause significant side effects and inhibit CYP enzymes
Solution Approach 1:
The patent modifies the chemical structure of existing AT2 agonists by changing specific parameters: replacing the carboxylic acid group with an amide group, modifying the aromatic ring substituents, and adjusting the alkyl chain length. These parameter changes in the molecular structure result in compounds that maintain AT2 receptor affinity while reducing CYP450 enzyme inhibition, thereby resolving the contradiction between therapeutic efficacy and harmful side effects
Solution Approach 2:
The invention applies local quality modification by specifically targeting the functional groups responsible for CYP450 interaction while preserving the core pharmacophore necessary for AT2 receptor binding. The modified compounds maintain the essential amino acid residues and spatial configuration for receptor interaction but alter local chemical properties (such as replacing acid groups with amides) to reduce enzyme inhibition, thus achieving selective improvement in safety profile without sacrificing therapeutic effect
2Productivity
If current IPF treatments are administered, then disease progression is slowed modestly, but effectiveness is limited and safety is compromised
Solution Approach 1:
The patent implements parameter changes in the molecular structure of AT2 agonists to enhance their pharmacological profile. By modifying the core structure (replacing carboxylic acid with amide, adjusting aromatic substituents), the compounds achieve improved metabolic stability and reduced off-target effects, thereby increasing both the reliability and productivity of the treatment for IPF patients
Solution Approach 2:
The invention creates optimized copies of existing AT2 agonists by synthesizing analogues with modified chemical structures. These copied compounds retain the fundamental pharmacological activity toward AT2 receptors but incorporate structural improvements that enhance safety and effectiveness, providing superior alternatives to current IPF treatments
3Reliability
If selective AT2 receptor agonists are developed with improved metabolic stability, then therapeutic outcomes are enhanced, but compound complexity increases
Solution Approach 1:
The patent achieves improved metabolic stability through targeted parameter changes in the molecular structure. By systematically modifying specific functional groups (acid to amide conversion, aromatic ring substitution patterns) rather than completely redesigning the molecule, the invention enhances metabolic stability while controlling the increase in structural complexity to manageable levels
Data Source
AI summary
There is provided pharmaceutical compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.